Aspire BioPharma is trading at $8.65, up +6.00%, with no verified fresh company catalyst explaining the after-hours rise. - The price is 6.00% above the October 26 regular-session close of $8.16. - No company-specific announcement or market-headlines listing item was identified for October 26; the latest surfaced press releases were from September. - Broader market signals were mixed, and the available evidence does not establish a market-wide explanation.